romiplostim (nplate) Report issue

Small molecule Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Romiplostim, sold under the brand name Nplate among others, is a fusion protein analog of thrombopoietin, a hormone that regulates platelet production.   Wikipedia

Chemistry

  • SMILES: Cc1cc(C)c(\C=C\2/C(=O)Nc3ccccc23)[nH]1
  • InChIKey: WUWDLXZGHZSWQZ-WQLSENKSSA-N
  • Mol. Mass: 238.29
  • ALogP: 3.12
  • ChEMBL Molecules:
    romiplostim  
    semaxanib  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$425.6552 - $851.3104

United States

$710.2400 - $3918.5000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one | amg531 | amg 531 | amg-531 | amgen megakaryopoiesis protein 531 | nplate | romiplostim | semaxanib | semaxinib | su5416 | su 5416 | su-5416

Organizations (52)

Research & Development (52)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (47)

Approved Indications (1)


 

Purpura, Thrombocytopenic, Idiopathic

Experimental Indications - Clinical Trial Phases 1-4 (47)


 

Adenocarcinoma (Phase 1/Phase 2)

Anemia (Phase 4)

Anemia, Aplastic (Phase 2/Phase 3)

Anemia, Refractory (Phase 1/Phase 2)

Bone Marrow Failure Disorders (Early Phase 1)

Brain Neoplasms (Phase 1/Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Colonic Neoplasms (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Fallopian Tube Neoplasms (Phase 1)

Gastrointestinal Stromal Tumors (Phase 2)

Glioblastoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hematologic Neoplasms (Phase 1)

Hematopoietic Stem Cell Transplantation (Phase 1/Phase 2)

Hepatitis C, Chronic (Phase 2)

HIV Infections (Phase 2)

Hodgkin Disease (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 1/Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 2)

Mesothelioma, Malignant (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 1)

Pharmacokinetics (Phase 1)

Prostatic Neoplasms (Phase 2)

Purpura (Phase 2/Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic ()

Purpura, Thrombotic Thrombocytopenic (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Kaposi (Phase 2)

Therapeutic Equivalency (Phase 1)

Thrombocytopenia (Phase 4)

Uterine Cervical Neoplasms (Phase 2)

Wiskott-Aldrich Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 92
  • # of Trial Organizations: 52

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue